| DAY 1 | F7 | F1 | G4 | Exhibit Hall | DAY 1 |
| 8:00 |
|
|
|
Arrival, Registration & Coffee |
8:00: |
| 8:05: |
|
|
|
8:05: |
| 8:10: |
|
|
|
8:10: |
| 8:15: |
|
|
|
8:15: |
| 8:20: |
|
|
|
8:20: |
| 8:25: |
|
|
|
8:25: |
| 8:30: |
|
|
|
8:30: |
| 8:35: |
|
|
|
8:35: |
| 8:40: |
|
|
|
8:40: |
| 8:45: |
|
|
|
8:45: |
| 8:50: |
|
|
|
8:50: |
| 8:55: |
|
|
|
8:55: |
| 9:00 |
|
|
|
9:00: |
| 9:05: |
|
Opening Remarks & Introduction of Keynote Speaker
09:05 (10 mins)
Mike Jowett, Horizon Discovery
|
|
9:05: |
| 9:10: |
|
|
|
9:10: |
| 9:15: |
|
Open Innovation for Sustainable Medicines R&D
09:15 (60 mins)
Mark Bamford, GlaxoSmithKline
|
|
|
9:15: |
| 9:20: |
|
|
|
9:20: |
| 9:25: |
|
|
|
9:25: |
| 9:30: |
|
|
|
9:30: |
| 9:35: |
|
|
|
9:35: |
| 9:40: |
|
|
|
9:40: |
| 9:45: |
|
|
|
9:45: |
| 9:50: |
|
|
|
9:50: |
| 9:55: |
|
|
|
9:55: |
| 10:00 |
|
|
|
10:00 |
| 10:05 |
|
|
|
10:05 |
| 10:10 |
|
|
|
10:10 |
| 10:15 |
|
|
|
Coffee Break |
10:15 |
| 10:20 |
|
|
|
10:20 |
| 10:25 |
|
|
|
10:25 |
| 10:30 |
|
|
|
10:30 |
| 10:35 |
|
|
|
10:35 |
| 10:40 |
|
|
|
10:40 |
| 10:45 |
Session Chair Introductions
10:45 (10 mins)
Malcolm Haddrick, AstraZeneca
|
Session Chair Introductions
10:45 (10 mins)
Vinoj George, Centre for Biomolecular Sciences (CBS), University of Nottingham
|
Session Chair Introductions
10:45 (10 mins)
Ian Waddell , Cancer Research UK
|
|
10:45 |
| 10:50 |
|
10:50 |
| 10:55 |
Epigenetic "Mutagens": Do They Exist? How Might We Identify Them?
10:55 (30 mins)
Richard M Walmsley, Gentronix Ltd - Uni.Manchester
|
Are All iPSC-Derived Cardiomyocytes Electrically Equal?
10:55 (30 mins)
Godfrey Smith, Clyde Bioscience
|
The Only Way Is… Open Access - Generating Affordable and Pioneer Treatments for Chronic and Rare Diseases
10:55 (30 mins)
Wen Hwa Lee, Structural Genomics Consortium, University of Oxford
|
|
10:55 |
| 11:00 |
|
11:00 |
| 11:05 |
|
11:05 |
| 11:10 |
|
11:10 |
| 11:15 |
|
11:15 |
| 11:20 |
|
11:20 |
| 11:25 |
Use of Human Liver Microtissues for Drug Safety Assessment
11:25 (30 mins)
Dominic Williams, Astrazeneca Cambridge
|
A Novel Approach to Functional Screening of Neuronal Excitability and Plasticity in Primary Neurons
11:25 (30 mins)
Paul Karila , Cellectricon
|
Edinburgh Cancer Discovery Unit (ECDU) and Edinburgh Phenotypic Assay Development Centre (E-PAD): Building Synergistic Alliances with Industry
11:25 (30 mins)
Neil Carragher, University of Edinburgh
|
|
11:25 |
| 11:30 |
|
11:30 |
| 11:35 |
|
11:35 |
| 11:40 |
|
11:40 |
| 11:45 |
|
11:45 |
| 11:50 |
|
11:50 |
| 11:55 |
Screening for Cell Death - A Comparison of Methods
11:55 (15 mins)
Lisa McWilliams, AstraZeneca
|
Inhibition of SMARCA2: a Novel Target for SMARCA4-Deficient Lung Adenocarcinoma
11:55 (15 mins)
Nikki March, Cancer Research UK Manchester Institute
|
Development of a High-Content Platform to Characterise Large Numbers of Induced Pluripotent Stem Cell Lines
11:55 (15 mins)
Natalie Moens, Centre for Stem Cells and Regenerative Medicine, King's College London
|
|
11:55 |
| 12:00 |
|
12:00 |
| 12:05 |
|
12:05 |
| 12:10 |
High Efficiency Differentiation and Maturation of Human Pluripotent Stem Cell (hPSC)-derived Cardiomyocytes
12:10 (15 mins)
Minh Duc Hoang , University of Nottingham
|
Co-Culture Spheroids for Phenotypic Preclinical Assessment of Direct Drug Delivery to Pediatric Brain Tumours
12:10 (15 mins)
Deylan Ivanov, University of Nottingham
|
|
|
12:10 |
| 12:15 |
|
|
12:15 |
| 12:20 |
|
|
12:20 |
| 12:25 |
DRAQ7™: Far-Red Real-Time Viability Monitoring, Cell-by-Cell
12:25 (5 mins)
Roy Edward, BioStatus Limited
|
An Automated Approach to High Content Screening
12:25 (5 mins)
David Ley, Peak Analysis & Automation
|
RFID... The way Forward in Cryo-Storage
12:25 (5 mins)
Colin Thorne, Cryogatt
|
|
12:25 |
| 12:30 |
Cell Viability Assessment in 3D Cultures With CellTiter-Glo® 3D Cell Viability Assay Reagent
12:30 (5 mins)
Craig Malcolm, Promega
|
Cytation™ 5 Cell Imaging Multi-Mode Microplate Reader: An Overview
12:30 (5 mins)
Lindsay Wood, BioTek Instruments
|
Open Innovation with Sygnature Discovery
12:30 (5 mins)
Lyn Parkinson, Sygnature Discovery
|
|
12:30 |
| 12:35 |
LabLogic Introduces the Hidex Sense Multi-Technology Microplate Reader – Performance at your Fingertips
12:35 (5 mins)
Anna Groom, LabLogic
|
Maximising Data Generation From Every Cell Imaging Experiment
12:35 (5 mins)
Jonathan Sheard, CM Technologies Oy
|
LightSwitch™ Custom Services : Gene Regulation Services to Help Accelerate Your Research
12:35 (5 mins)
Priya Karan, Active Motif
|
|
12:35 |
| 12:40 |
Using Impedance-Based Approaches for Measuring Cell-Mediated Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
12:40 (5 mins)
Jay Champaneri , Cambridge Bioscience
|
VIAFLO ASSIST – Your Personal Pipetting Assistant
12:40 (5 mins)
Sharon Barnard , Integra
|
TBD
12:40 (5 mins)
Rachel Shuker, DiscoveRx
|
|
12:40 |
| 12:45 |
The CLARIOstar - Offering Flexibility & Sensitivity
12:45 (5 mins)
Catherine Wark, BMG Labtech
|
Celigo S Imaging Cytometer for 2D and 3D ImmunoOncology Research
12:45 (5 mins)
Scott Cribbes, Nexcelom BioScience Ltd
|
BlueCatBio BlueWasher: Contact-Free, Near Zero Residual Volume Microplate Washing and Media Changes
12:45 (5 mins)
Kerstin Hagen-Mann , BlueCatBio
|
|
12:45 |
| 12:50 |
|
|
|
|
12:50 |
| 12:55 |
|
|
|
Lunch - Exhibition - Posters |
12:55 |
| 1:00 |
|
|
|
1:00: |
| 1:05: |
|
|
|
1:05: |
| 1:10: |
|
|
|
1:10: |
| 1:15: |
|
|
|
1:15: |
| 1:20: |
|
|
|
1:20: |
| 1:25: |
|
|
|
1:25: |
| 1:30: |
|
|
|
1:30: |
| 1:35: |
|
|
|
1:35: |
| 1:40: |
|
|
|
1:40: |
| 1:45: |
|
|
|
1:45: |
| 1:50: |
|
|
|
1:50: |
| 1:55: |
|
|
|
1:55: |
| 2:00 |
Towards a New Paradigm in Genetic Toxicology: From Qualitative to Quantitative Approaches
14:00 (30 mins)
George Johnson, Swansea University
|
Generation of Human Cellular Models for Drug Screening Using CRISPR/Cas9 Technology
14:00 (30 mins)
Viola Borgdorff, University of Nottingham
|
Drug Discovery in an Academic Setting - the Best of Both Worlds?
14:00 (30 mins)
Simon Ridley, Alzheimer’s Research UK
|
|
2:00: |
| 2:05: |
|
2:05: |
| 2:10: |
|
2:10: |
| 2:15: |
|
2:15: |
| 2:20: |
|
2:20: |
| 2:25: |
|
2:25: |
| 2:30: |
In Vitro Generation of Functional Organoid Structures Resembling Embryonic Liver Buds Using Differentiated Human Cells
14:30 (30 mins)
Katja Breitkopf-Heinlein, University of Heidelberg
|
Developing Novel Biomaterials-Based Platforms for Translational Applications
14:30 (30 mins)
Lesley Chow, Imperial College London
|
New Ways to Fund Early Stage Drug Discovery and Development From an Early Stage Investor's Perspective
14:30 (30 mins)
Robert James, Sixth Element Capital
|
|
2:30: |
| 2:35: |
|
2:35: |
| 2:40: |
|
2:40: |
| 2:45: |
|
2:45: |
| 2:50: |
|
2:50: |
| 2:55: |
|
2:55: |
| 3:00 |
Novel Methods to Measure Cell Viability in Real Time Enables Multiplexing Opportunities
15:00 (30 mins)
Terry Riss, Promega Corporation
|
Innovative Use of Scaffolding Materials to Support 3D Cell Growth and Build Improved In Vitro Assays
15:00 (30 mins)
Stefan Przyborski, CSO, Reinnervate Limited
|
Open innovation in practice: An Automated High Throughput Imaging Screen for the Identification of Anti-Wolbachia Agents
15:00 (30 mins)
Rachel Clare, Liverpool School of Tropical Medicine (LSTM)
|
|
3:00: |
| 3:05: |
|
3:05: |
| 3:10: |
|
3:10: |
| 3:15: |
|
3:15: |
| 3:20: |
|
3:20: |
| 3:25: |
|
3:25: |
| 3:30: |
|
|
|
Coffee Break |
3:30: |
| 3:35: |
|
|
|
3:35: |
| 3:40: |
|
|
|
3:40: |
| 3:45: |
|
|
|
3:45: |
| 3:50: |
|
|
|
3:50: |
| 3:55: |
|
|
|
3:55: |
| 4:00 |
Automation Platforms for Stem Cells and Heart Disease
16:00 (30 mins)
Chris Denning, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling (STEM), University of Nottingham
|
Profiling Compounds in Primary Human Cell BioMAP® Systems For Drug Discovery and Therapeutic Development in Inflammation and Cancer
16:00 (30 mins)
Andrew Baxter, DiscoveRx Corporation
|
Nothing Ventured Nothing Gained: Supporting Innovation via Novel Venture Collaborations
16:00 (30 mins)
Ashwani Bahl, Eli Lilly and Company
|
|
4:00: |
| 4:05: |
|
4:05: |
| 4:10: |
|
4:10: |
| 4:15: |
|
4:15: |
| 4:20: |
|
4:20: |
| 4:25: |
|
4:25: |
| 4:30: |
Advanced In Vitro Models: The Future of Early Cardiovascular Safety Testing?
16:30 (30 mins)
Chris Pollard, AstraZeneca
|
Novel Assays for Immuno-Oncology Using Kinetic Live Cell Imaging
16:30 (30 mins)
Nicola Bevan, Essen Bioscience
|
Drug Discovery Through Academic/Industry Collaboration
16:30 (30 mins)
Allan Jordan, CRUK Manchester Institute
|
|
4:30: |
| 4:35: |
|
4:35: |
| 4:40: |
|
4:40: |
| 4:45: |
|
4:45: |
| 4:50: |
|
4:50: |
| 4:55: |
|
4:55: |
| 5:00 |
|
|
|
Close of Conference |
5:00: |
| 5:05: |
|
|
|
5:05: |
| 5:10: |
|
|
|
5:10: |
| 5:15: |
|
|
|
5:15: |
| 5:20: |
|
|
|
5:20: |
| 5:25: |
|
|
|
5:25: |
| 5:30: |
|
|
|
|
5:30: |
| 5:35: |
|
|
|
|
5:35: |
| 5:40: |
|
|
|
|
5:40: |
| 5:45: |
|
|
|
|
5:45: |
| 5:50: |
|
|
|
|
5:50: |
| 5:55: |
|
|
|
|
5:55: |
| 6:00 |
|
|
|
|
6:00: |
Print